The U.S. Food and Drug Administration (FDA) has approved the Alere Determine HIV-1/2 AF/Ab Combo test that can detect an HIV infection and distinguish between an early infection and an established HIV infection from "human serum, plasma, and venous or fingerstick whole-blood specimens." Developed by Alere's Israel-based Orgenics subsidiary, the Alere Determine rapid HIV test not only would provide faster HIV diagnosis, but also would be relatively simple to use in remote high-incidence areas such as sub-Saharan Africa.
View Full Article
The Alere Determine rapid test is able to detect simultaneously the HIV-1 p24 antigen, a signal of HIV-1 infection, and the presence of HIV-1 and HIV-2 antibodies usually present in established infections. Most worldwide AIDS cases developed from HIV-1 infections, and HIV-2 infections have occurred mostly in West Africa. The Alere Determine test is not useful for screening blood donors because it does not distinguish between HIV-1 antibodies and HIV-2 antibodies.
Comment by: dick keiser
Wed., Aug. 14, 2013 at 9:40 am EDT
so why does the CDC continue to report as a matter of fact the 1:5 that don't know status and the 50,000 new infections a year. We could end or at least traumatically lower new infections if anyone cared! this is now the 12th year of these 'routine' statistics.
HIV is now 50 billion a year in the US .. my latest blog will suggest the epidemic is not sustainable financially at current level
and passive hiv testing is not going to route out the 1:5 and get them on anti-virals and non-infectious .. neither are men who last tested negative, continuing to sero sort for bb sex
dick keiser huffington post, author upcoming book
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy